Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking forward to earnings on August 15th. Any thoughts?
Insider buying 2
8/17/2007 M 116172 A $0.1 283166 D
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=5382194
Insider buying
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=5385117
Common Stock, par value $0.01 per share 08/20/07 P 3,000 A $10 19,500 D
Common Stock, par value $0.01 per share 08/21/07 P 2,000 A $10.03 21,500 D
Common Stock, par value $0.01 per share 08/21/07 P 3,000 A $10.18 24,500 D
outstanding at July 31, 2007:
20,424,094
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=5359761
Hey guys, I dont see a problem with a bit of heated discussion. Everybody is entitled to their opinions and I believe its good for the integrity of the board.
Lets just keep it friendly and not get too personal. IHUB is where I come to get away from boards like YAHOO and RagingBull.
;)
Just my opinion.
Good luck all.
-Scream
Physicians Formula Holdings Inc. closes up on upgrade
Jennifer Schonberger | Aug 20, 2007 5:15pm EDT | User Rating N/A
Shares of Physicians Formula Holdings Inc. (Nasdaq: FACE) closed higher today after Citigroup upgraded the cosmetics company to a “buy” rating from “hold” and increased its target price to $13 from $12.
Citigroup analyst Wendy Nicholson said she thinks the stock has bottomed out from a fundamental and valuation standpoint and “now offers an attractive entry point.”
Shares of Physicians Formula have declined 60% since April on account of negative earnings revisions, poor communication from management and an overall weaker consumer spending environment, according to Nicholoson. The company now trades at 13 times Nicholson’s revised calendar year 2008 EPS estimate.
http://www.smallcapinvestor.com/articles/small_cap_news/news/08/20/2007/physicians_formula_holdings_...
Broker Action For Monday, Aug. 20
Physicians Formula (nasdaq: FACE - news - people ) is getting some FACE time after pulling back its earnings forecast last week. A Citigroup analyst has upgraded the stock to “buy” from “hold” for the company, which owns a line of personal-care products, rejecting recent sentiment on the street that Americans aren’t shopping.
http://www.forbes.com/2007/08/20/countrywide-financial-mcgraw-markets-cx_ph_0820brokeraction.html?pa...
UPDATE 1-RESEARCH ALERT-Citigroup upgrades Physicians Formula
Adds details, share movement) Aug 20 (Reuters) - PHYSICIANS FORMULA HOLDINGS INC (FACE.O: Quote, Profile, Research) Current Prior
Rating Buy Hold
Price Target $13 $12 --Citigroup said it still expects the cosmetics company to
deliver 16 percent sales growth in 2008, despite the brokerage
having recently revised down its expectations for the company's
growth. --The brokerage raised its earnings estimates for the
company, saying the coming year would not be as pressured by
initial store setup expenses at Wal-Mart Stores Inc (WMT.N: Quote, Profile, Research) as
in the second quarter of 2007. --Citigroup now expects Physicians Formula to earn 2 cents
a share, compared with its previous view for a break even, in
the second quarter of 2008. For fiscal 2008, it expects the
company to earn 69 cents per share, up from the previous view
for a profit of 67 cents a share. --Shares of the company were up almost 11 percent at $10.03
in morning trade on the Nasdaq.
(Reporting by Neha Singh in Bangalore)
http://www.reuters.com/article/marketsNews/idUKBNG8160120070820?rpc=44
AP
Out of the Gate: Physicians Formula Up
Monday August 20, 10:02 am ET
Analyst Upgrades Physicians Formula Holdings Stock on Prediction of Strong 2008 Sales Growth
NEW YORK (AP) -- Shares of Physicians Formula Holdings Inc. gained ground Monday after a Citi Investment Research analyst upgraded the stock to "Buy," saying the cosmetics company will post strong sales growth in 2008.
The stock has lost more than half its value since May 8, when Physicians Formula said its second-quarter results would miss analyst estimates. The company cut its quarterly and full-year outlook in July, and lowered its 2007 forecast again on Tuesday.
Physicians Formula began trading in November, and set a low of $8.26 per share on Thursday.
Wendy Nicholson upgraded the stock to "Buy" from "Hold," and raised her price target to $13 per share from $12. She thinks the company's sales will grow 16 percent in 2008 -- better than its competitors -- and said Physicians Formula will increase its market share despite weak U.S. consumer spending.
Three analysts report a "Buy"-equivalent rating on the stock to Thomson Financial, while one gives a "Neutral" rating.
Shares advanced 82 cents, or 4.5 percent, to $9.87 in morning trading.
http://biz.yahoo.com/ap/070820/physicians_formula_out_of_the_gate.html?.v=1
Physicians Formula Holdings Upped To Buy From Hold At CitiLast update: 8/20/2007 7:12:04 AM(END) Dow Jones NewswiresAugust 20, 2007 07:12 ET (11:12 GMT)Copyright © 2007 MarketWatch, Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision. Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
ZVI EIFER - BUYS -
Common Stock, par value $0.01 per share 8/16/2007 P 7500 A $8.92 9500 D
Common Stock, par value $0.01 per share 8/17/2007 P 4000 A $9.41 13500 D
Common Stock, par value $0.01 per share 8/17/2007 P 3000 A $9.02
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=5379781
Jaeger Joseph J - CFO - BUYS
Common Stock, par value $0.01 per share 8/16/2007 M 50000 A
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=5379828
could you please remove me as a moderator assistance of this board?
TIA
Good luck
I sold today at .10 for a loss when i got in at .116. after reading about the dillution that will be taking place and the crooked CEO... this one is gonna be a tough play. Just my humble opinion.
Im out.
Good luck all. Do your own DD.
-screamster
Nanotechnology Expert to Head mPhase Subsidiary
Shankar P. General Assignment
8/14/2007
http://www.njbiz.com/article.asp?aID=71620
OUCH, post market hurts..premarket wont be much better im affraid
RPDI Rapid Fitness, Inc. Announces It Has Signed the Purchase Agreement with Caribbean Fitness, Inc., d/b/a America's Paradise Gym, a United States Virgin Islands Company with Three Fitness Centers
Might be a trillion at this point.
SMMW - Summus Works, Inc. Announces LOI for Acquisition of BioPharmetics, Inc. Assets
Last Update: 10:10 AM ET Aug 9, 2007
DENVER, Colo., Aug 9, 2007 (PrimeNewswire via COMTEX) -- Summus Works, Inc. (Pink Sheets:SMMW) announced the Company has signed a letter of intent to acquire the total assets of BioPharmetics, Inc. (Pink Sheets:BPMT). Some or all of the management of BioPharmetics, Inc. will be elected to the Board of Directors of the Company upon closing.
Three subsidiary divisions of BioPharmetics, Inc. provide quality durable medical equipment, diabetic supplies, and health, beauty, and anti-aging products to customer in the U.S., Canada, and over 23 countries throughout the world. The largest -- the pharmaceutical division -- distributes medical equipment and diabetes supplies, and dispenses physician-prescribed medications through its pharmacy partners. Additionally, the division works closely with a dealer network of health care companies and managed care facilities to provide superior pricing and customer support for Medicare, Medi-Cal, Medicaid and private insurance reimbursement programs.
The Biotechnology division is available for clients wanting to manufacture and test potential prescription medications and assist to facilitate the necessary FDA clinical trials in order to gain approval. The cosmetic division manages the distribution of the TOMA line of cosmetics as well as private label manufacturing for companies seeking to enter the market place with their own formulations and ideas. BioPharmetics, Inc. was founded in 2005 and is headquartered in Sun Valley, CA.
The acquisition remains subject to the execution of definitive agreements and the approval of the Company's Board of Directors. The closing date and further information will be released publicly. For more information visit http://www.biopharmetics.com.
The Summus Works, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4093
This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
This news release was distributed by PrimeNewswire, www.primenewswire.com
These stocks from the stocks up 25% plus in last 65 days list have not been dented by the correction.
FACE,Physicians Formula Holdings (Google Yahoo Earnings Chart)
http://stockbee.blogspot.com/2007/08/relative-strength.html
Awesome news..esp for this oversold stock! CLEAR!! ;)
Biomira and Merck KGaA sign amended and restated collaboration and supply agreements related to Stimuvax(R)
http://www.marketwatch.com/news/story/biomira-merck-kgaa-sign-amended/story.aspx?guid=%7B43FD62A1%2D...
BIOM - Biomira and Merck KGaA sign amended and restated collaboration and supply agreements related to Stimuvax(R)
Last Update: 8:00 AM ET Aug 8, 2007
EDMONTON, Aug 08, 2007 /PRNewswire-FirstCall via COMTEX/ -- Biomira Inc. (BIOM : biomira inc com
News , chart , profile , more
Last: 0.96-0.01-1.03%
8:02am 08/08/2007
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
BIOM0.96, -0.01, -1.0%) (CA:BRA: news, chart, profile) today announced the signing of amended and restated collaboration and supply agreements related to Stimuvax(R) with Merck KGaA of Darmstadt, Germany. The amended agreements restructure the agreements originally signed in 2001, and are based upon the letter of intent signed in January 2006. Stimuvax is an innovative investigational therapeutic cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a protein antigen widely expressed on common cancers. Merck KGaA currently is conducting a global Phase 3 trial of Stimuvax in patients with unresectable Stage III non-small cell lung cancer (NSCLC).
Under the terms of the restated agreements, Merck will have world wide marketing rights to and will be entirely responsible for the further clinical development of Stimuvax. Biomira is entitled to development and sales-based milestone payments and a royalty on net sales. Biomira retains responsibility for the manufacture of Stimuvax, including process development and scale-up for commercial manufacturing. Merck will exclusively purchase Stimuvax from Biomira; with respect to purchases for commercial sales, the purchase price will be subtracted from Biomira's royalty. The restated agreements provide Biomira with revised payments based on certain milestones related to manufacturing scale-up and process transfer. Biomira also will receive a payment of U.S. $2.5 million upon clearance of the transaction with the U.S. anti-trust authorities.
"We are pleased to conclude these revised agreements with Merck, enhancing our relationship for this exciting product," said Dr. Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "Given the significant clinical and commercial potential for Stimuvax, we believe that Merck KGaA's expertise and resources in global clinical development, sales and marketing will help to bring this innovative vaccine to as many patients as possible. Merck KGaA has demonstrated its ability to bring important new cancer therapies to market, and we believe this collaboration will enable robust and efficient development of Stimuvax in NSCLC and, potentially, several additional cancer indications."
Merck KGaA and its U.S. affiliate, EMD Serono, Inc., currently are conducting a Phase 3 trial of Stimuvax in patients with unresectable Stage III NSCLC. This global trial, known as START (Stimulating Targeted Antigenic Responses To NSCLC) is expected to enroll more than 1,300 patients in approximately 30 countries. The trial is designed to assess survival in patients receiving best supportive care and Stimuvax compared with patients receiving best supportive care alone.
Financial Guidance
Biomira believes the following financial guidance to be correct as of the date provided. We are providing this guidance as a convenience to investors, and we assume no obligation to update it.
Based on the terms of the restated and amended supply and collaboration agreements with Merck announced herein, Biomira is updating its prior financial guidance. The restated agreements provide for near-term payments which Biomira believes are sufficient to fund its operations at current levels for approximately an additional six months. Biomira currently anticipates receiving a substantial portion of these milestones before the end of 2008. As a result, the Company believes that it currently has sufficient cash resources to last through the end of fiscal 2008.
About the START Trial
The START trial is a randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage III NSCLC who have had a response or stable disease after at least two cycles of platinum based chemo-radiotherapy. The study has been designed considering scientific advice from the European Medicines Agency (EMEA/CHMP) and has been agreed upon with the U.S. Food and Drug Administration (FDA) through a Special Protocol Assessment (SPA). Data from a randomized Phase IIb trial described below encouraged the initiation of the Phase III program.
Physicians Formula Holdings, Inc. Announces that Executive Zvi Eiref to Join the Company's Board as an Independent Director
Last Update: 4:05 PM ET Aug 7, 2007
AZUSA, Calif., Aug 07, 2007 /PRNewswire-FirstCall via COMTEX/ -- Physicians Formula Holdings, Inc. today announced that it has appointed Zvi Eiref to join the Company's Board of Directors as an independent director effective August 6, 2007. The Company also announced that Walter G. Kortschak resigned as a director, effective August 6, 2007, to devote more time to his other business activities.
Mr. Eiref brings over 30 years of operating experience in the consumer packaged goods industry to his Board position. During his 20-year tenure as Chief Financial Officer of Church & Dwight Co., Inc. Mr. Eiref worked with the executive team to help shape overall corporate strategy and transform Church & Dwight from a small single product company to a broad-based household and personal care company with annual sales of $2 billion. From 1988 to 1995 Mr. Eiref served as Chief Financial Officer of Chanel, Inc., where he professionalized the finance and systems functions during a period of very rapid growth in Chanel's fragrance, cosmetics and ready-to-wear businesses. Earlier in his career, Mr. Eiref worked for Unilever and Arthur Andersen in Europe, and he is an English Chartered Accountant.
"I am very pleased to welcome Zvi to our Board and I look forward to working closely with him as we continue to extend the Physicians Formula brand," said Ingrid Jackel, Chief Executive Officer. "Zvi brings a wealth of public company operational and financial experience, and his insight will be invaluable to us as we continue to launch new products and expand our market share. I would also like to thank Walter for his valued input and contribution over the past four years."
"I am honored to serve on the Board of Physicians Formula," said Zvi Eiref. "With their strong management team and leadership position in the masstige market, the Company is well positioned for long-term sustainable growth. I look forward to working closely with the Company's executive team and other Board members."
http://www.marketwatch.com/news/story/physicians-formula-holdings-inc-announces/story.aspx?guid=%7B9...
Financials (In millions of USD)
http://finance.google.com/finance?q=OTC%3ARBCL
Key Stats & Ratios
Quarterly
(Mar '07) Annual
(2006) Annual
(TTM)
Net Profit Margin 6.03% 2.02% 3.59%
Operating Margin 10.98% 4.46% 6.88%
EBITD Margin - 7.39% 9.43%
Return on Average Assets 9.11% 3.34% 5.68%
Return on Average Equity 23.05% 8.44% 14.92%
Employees 70
http://finance.google.com/finance?q=OTC%3ARBCL
Email from FACE Inv. Relations:
xxxx,
I apologize for the late reply ... I was out on a personal day yesterday.
Regarding your question, the difference between the 13.9 million and the 14.5 million is that the 13.9 million represent basic shares outstanding. The 14.5 million represent dilutive shares outstanding (basic plus options outstanding).
I hope this helps you. If you need any further help, feel free to contact me.
Richard J. Almeida
Physicians Formula Holdings, Inc.
(626) 334-3395, Ext. 1246
Ownership Activity
Description # of Holders Shares
Total Positions 69 14,018,772
New Positions 23 2,479,071
Soldout Positions 26 -2,239,511
Net Position Change 5 2,096,236
Buyers 50 5,049,238
Sellers 45 -2,953,002
http://moneycentral.msn.com/ownership?Symbol=FACE
Physicians Formula Holdings, Inc.: Ownership
Shares Outstanding 14.00 Mil
Institutional Ownership (%) 100.70
Top 10 Institutions (%) 65.20
Mutual Fund Ownership (%) 22.17
5%/Insider Ownership (%) 1.63
Float (%) 98.37
http://moneycentral.msn.com/ownership?Symbol=FACE
What: Physicians Formula Mineral Wear Mineral Eyeliner Pencil in Dark Brown
http://www.shefinds.com/blog/index.php/weblog/link/beauty_find_eyeliner_that_doesnt_tug/#
These stocks from the stocks up 25% plus in last 65 days list have not been dented by the correction. Some of these started rallying during the correction and are likely leader for next phase of the rally.
FACE,Physicians Formula Holdings (Google Yahoo Earnings Chart)
http://stockbee.blogspot.com/2007/08/relative-strength.html
RCBL trading at 52 week high today
Looks like MM's are shaking to make another run up. Building some support in the 14's. JMO.
good luck
BIOM , soon. IMO
TWX , FACE off a bottom play..still room for movement.
RBCL - Second Quarter Earnings 74 Percent Higher
http://www.marketwatch.com/news/story/rbc-life-sciences-reports-second/story.aspx?guid=%7B9D657187%2...
RBCL today Change:+0.13 +18.31%
http://investorshub.advfn.com/boards/board.asp?board_id=9877
FACE tops 50 day moving average!
Physicians Formula Holdings, Inc. Announces Second Quarter 2007 Conference Call to be held on Monday, August 13, 2007
Last Update: 4:01 PM ET Jul 31, 2007
AZUSA, Calif., July 31, 2007 /PRNewswire-FirstCall via COMTEX/ -- Physicians Formula Holdings, Inc. (FACE : physicians formula hldgs inc com
News , chart , profile , more
Last: 14.95+0.23+1.56%
4:22pm 07/31/2007
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
FACE14.95, +0.23, +1.6%) today announced that the Company will host a conference call to discuss its results for the second quarter ended June 30, 2007, on Monday, August 13, 2007. The Company will issue an earnings announcement prior to the conference call.
The conference call is scheduled to begin at 2:00 pm Pacific Time on Monday, August 13, 2007. Participants may access the call by dialing 800-811- 8845 (domestic) or 913-981-4905 (international). In addition, the call will be webcast via the Company's Web site at www.physiciansformula.com, Investor Relations, where it will also be archived. A telephone replay will be available through Monday, August 27, 2007. To access the replay, please dial 888-203-1112 (domestic) or 719-457-0820 (international), passcode 2682414.
About Physicians Formula Holdings, Inc.
Physicians Formula is one of the fastest growing cosmetics companies operating in the mass market prestige, or "masstige", market. Under its Physicians Formula brand name, created in 1937, the Company develops, markets and distributes innovative, premium priced products for the mass market channel. Physicians Formula differentiates itself by addressing skin imperfections through a problem-solving approach, rather than focusing on changing fashion trends. Currently, Physicians Formula products are sold in over 26,000 stores throughout the U.S. including stores operated by Wal-Mart, Target, CVS, Walgreens and Albertsons.
(FACE/F)
Contact: John Mills / Anne Rakunas
Integrated Corporate Relations, Inc.
(310) 954-1100
SOURCE Physicians Formula Holdings, Inc.
John Mills or Anne Rakunas both of Integrated Corporate Relations, Inc., +1-310-954-1100, for Physicians Formula Holdings, Inc. http://www.physiciansformula.com/ Copyright (C) 2007 PR Newswire. All rights reserved
http://www.marketwatch.com/news/story/physicians-formula-holdings-inc-announces/story.aspx?guid=%7BE...